The 5-year survival rate of CD63-positive tumor patients was significantly lower than that of CD63-negative tumor patients (p<0.001), suggesting that the expression of CD63 is an important independent factor for the prognosis of gastric cancer patients (35). This evidence concerns the gene CD63 and gastric cancer.